Correct. It was never an impossibility, even without resorting to the ADAS-Cog/CDR-SB approach, and I am sure the FDA will throw away its rulebook -- OK, set of guidances -- to rush through approvals under the new CNPV program.
Market Data 
Markets 
AI
